ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un podcast de American College of Cardiology - Les mardis
Catégories:
Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a multicenter, randomized, double-blind, placebo-controlled study presented at ACC.23/WCC. In this interview, Bonnie Ky MD, MSCE and Anthony N. DeMaria MD, MACC discuss “Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial.” Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
